Development

The FDA fast-tracks a drug for undruggable RAS

development2026-01-05

Claim

The FDA granted breakthrough status to daraxonrasib for pancreatic cancer, targeting undruggable RAS mutations with 8.8 months of progression-free survival.

Reported metric: 8.8 months

Reporting date: 2026-01-05 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to January 5, 2026 (theinnermostloop.substack.com)

Knowledge graphopen in browser →

Reported in

Welcome to January 5, 2026

Actor

Evidence for

Referenced by

Welcome to January 5, 2026

Cite or correct this record

Citation formatCitation text

The FDA fast-tracks a drug for undruggable RAS
Innermost Loop KB — secondary record
Reporting date: 2026-01-05
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-01-05-daraxonrasib-breakthrough
Claim: The FDA granted breakthrough status to daraxonrasib for pancreatic cancer, targeting undruggable RAS mutations with 8.8 months of progression-free survival.
Attributed sources:
- Welcome to January 5, 2026 — https://theinnermostloop.substack.com/p/welcome-to-january-5-2026
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.